199 results about "Mucoproteins" patented technology

The invention provides an antibody specifically combined with CDH6 (cadherin 6) and application thereof, and particularly discloses mouse and humanized antibodies combined with CDH6 as well as a preparation method and application thereof, and the mouse and humanized antibodies have better affinity with CDH6 protein and better endocytosis activity, so that the mouse and humanized antibodies can be applied to preparation of medicines for treating tumors and the like.

The invention discloses a polyphenol-based tissue adhesive for promoting wound healing and a preparation method thereof, and relates to the technical field of medical tissue adhesives. The preparation method of the tissue adhesive comprises the following steps: step 1, preparing a polyphenol compound and recombinant mussel mucin into a solution, and uniformly stirring for later use, namely a solution A; 2, preparing a temperature response type high polymer material into a solution for later use, namely a solution B; and 3, mixing the solution A prepared in the step 1 and the solution B prepared in the step 2, fully and uniformly mixing, shaking and centrifuging, and discarding the supernatant. By selecting the temperature response type high polymer material, the tissue adhesive is endowed with the characteristic of temperature sensitivity, so that the modulus of the adhesive at the human body temperature is improved, and the colloid contraction can further promote wound closure. The mussel mucin is introduced to stimulate collagen regeneration of the wound part, activate the immune mechanism and remodel the wound microenvironment so as to achieve the purpose of promoting healing.

The invention is suitable for the technical field of gynecological gels, and provides a gynecological gel with a repairing effect. Comprising the following components in percentage by weight: 0.1%-0.5% of recombinant III type human collagen, 0.05%-0.2% of mussel mucin, 1%-3% of chitosan, 0.2%-1% of sodium hyaluronate, 2%-5% of lactobacillus fermentation product filtrate, 0.05%-0.2% of tea tree essential oil, 0.2%-0.5% of carbomer, 0.1%-0.4% of triethanolamine, 0.1%-0.2% of sodium methylparaben and the balance of purified water. The gynecological gel with the repairing effect has the excellent repairing effect, integrates multiple effects of effectively resisting bacteria and diminishing inflammation, promoting repairing of damaged vaginal mucosa, adjusting vaginal micro-ecological balance and the like, not only can efficiently inhibit growth of various pathogens, but also can remarkably promote proliferation and repairing of vaginal mucosa cells, and has the advantages that the repairing effect is good, and the repairing effect is good. The vaginal micro-ecological balance can be accurately adjusted, no stimulation is caused to vaginal mucosa, safety and reliability are achieved, and long-term use can be achieved.

The invention provides application of G3BP1 in preparation of a medicine for protecting barrier function integrity of vascular endothelial cells, and belongs to the technical field of biological medicine manufacturing. The invention provides application of G3BP1 in preparation of a medicine for protecting barrier function integrity of vascular endothelial cells. The present invention relates to G3BP1 that ensures the sustained expression of key adherent junction proteins (VE-cadherin, p120) by directly binding to and stabilizing the mRNA of these proteins; meanwhile, the G3BP1 is combined with the MYD88mRNA to promote the degradation of the MYD88mRNA, so that a permeability-promoting MYD88-ARNO-ARF6 signal channel is inhibited, especially under the condition of an inflammation period. Therefore, the G3BP1 regulates and maintains the integrity of the vascular barrier through double transcription, and a new treatment strategy is provided for damage repair of the functional integrity of the vascular endothelial cell barrier.

The invention relates to a Raman probe for detecting hydrogen sulfide as well as a preparation method and application of the Raman probe. The gold and silver nanocage (AuAg NCs) is prepared, and after the gold and silver nanocage (AuAg NCs) is modified by a Raman signal molecule 4-ethynylaniline (4EA), it is found that the AuAg-4EANCs shows the strongest Raman enhancement effect at the position of 2010 cm <-1 > located in a cell silence zone. The SERS probe with the tumor targeting capability is developed through the functional modification of a mucoprotein 1 aptamer (MUin1aptamer, MUC1Apt) and polyethylene glycol (PEG), and the SERS probe with the tumor targeting capability is further developed through the functional modification of the mucoprotein 1 aptamer (MUin1aptamer, MUC1Apt) and the PEG (Polyethylene Glycol). In the presence of hydrogen sulfide (H2S) and oxygen, Ag in AuAg-4EANCs rapidly reacts with H2S to generate Ag2S with significantly reduced Raman enhancement performance, resulting in sharp attenuation of 4EA signal intensity. And along with the increase of the H2S concentration, the generation amount of Ag2S is increased, so that a quantitative detection model dependent on the H2S concentration is established.

The present invention provides an isolated Akkermansia muciniphila strain, composition comprising the same, and use thereof, which can be used for treating, preventing, or alleviating obesity, metabolic disorders induced by obesity, diabetes, inflammation, liver and kidney diseases, liver diseases, cardiovascular and cerebrovascular diseases, brain aging, tumors, etc. Additionally, it can be used for preventing and treating metabolic disorders after discontinuation of GLP-1 receptor agonist drugs, preventing weight rebound and blood glucose rebound, and maintaining glucose homeostasis.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

The application discloses a preparation method of high-purity recombinant mussel adhesive protein and belongs to the technical field of recombinant protein preparation. The amino acid sequence of Mfp-3 of Mytilus coruscus and the partial peptide segment of the amino acid sequence of preCol-D of Mytilus edulis are fused and expressed according to the idea of improving target protein expression by using fusion protein, and the improvement of the induction, tyrosinase modification and separation and purification process is combined to obtain the recombinant mussel adhesive protein with high purity, low endotoxin content and good adhesion performance. The successful preparation of the recombinant mussel adhesive protein provides a new idea for the industrial production of the recombinant mussel adhesive protein, provides raw material support for the multi-field application of the recombinant mussel adhesive protein, realizes the preparation of the customized sequence recombinant mussel adhesive protein according to application requirements, and promotes the application of the mussel adhesive protein in different fields.

The present invention relates to Akkermansia muciniphila Akk11 having the functions of regulating blood glucose and blood fat and the use thereof. Said Akkermansia muciniphila Akk11 is classified and named as Akkermansia muciniphila Akk11 with the accession number of CCTCC NO: M2024119. The strain uses mucin as the unique source of carbon element and nitrogen element, so as to control the basic regulatory systems of glucose and energy metabolism, protect the integrity of intestinal epithelial cells and mucus layers to exert a protective effect on metabolism, regulate the levels of blood glucose and blood fat, and remarkably relieve symptoms of metabolic disorders, and thus providing strategies and reference basis for the prevention and treatment of obesity.

Disclosed herein are double stranded ribonucleic acids (dsRNAs) and synthetic antisense oligonucleotides (ASOs) for use in inhibiting the expression of MUC5B and in the treatment of a subject having a disease or disorder characterized by overexpression of MUC5B, including in subjects having lung disease or in a subject at risk of developing lung disease, for example, in a subject having or at risk of developing idiopathic pulmonary fibrosis.

The application provides a mussel mucin synthesis method and relates to the technical field of genetic engineering.The application improves the yield of mussel mucin by carrying out deletion mutation on the N-terminal sequence of the secondary structure of the mussel mucin amino acid sequence such as SEQ ID NO.1.The yield of mussel mucin in the prior art is about 2.57g / L, while the yield of mussel mucin in the application is about 5g / L, which is greatly improved compared with the yield of mussel mucin in the prior art.On this basis, the mussel mucin is modified by dopa through co-expression of tyrosinase, and the expression amount of the tyrosinase is controlled through different intensities of RBS, so as to regulate the modification degree of dopa, improve the yield of mussel mucin, and realize controllable modification of dopa in the mussel mucin, finally obtaining mussel mucin with high yield and different modification degrees of dopa.

The invention belongs to the technical field of biological detection, and discloses a sequence combination for rapidly detecting influenza A based on CRISPR / CAS12a-MIRA and application, the sequence combination comprises an MIRA primer pair (SEQ ID NO: 1-2) of a targeted influenza A virus M gene highly conserved region (M1 fragment), and CRISPR / Cas12a detection probes (crRNA SEQ ID NO: 3 and phosphorothioate modified FAM-biotin probe SEQ ID NO: 4). By optimizing a buffer system (containing PEG 8000 and betaine), MIRA amplification and CRISPR detection are continuously completed in a closed tube at 37-42 DEG C, and a result is output within 30 minutes. The detection sensitivity of the kit reaches 50 copies / [mu] L, the specificity is 100%, and subtypes such as H1N1, H3N2, H5N1 and H7N9 can be covered. Compared with the prior art, according to the scheme, the detection time is shortened by 67%, the probe cost is reduced by 80%, and high anti-interference performance (tolerance to 10% mucoprotein and 5% whole blood) is achieved. The kit is suitable for on-site instant detection of saliva, nasopharynx swabs and environmental samples, and an efficient and portable solution is provided for basic medical institutions and prevention and control of sudden epidemic situations.

The application discloses a plant lactobacillus strain and application thereof, and belongs to the technical field of microorganisms. The preservation number of the strain is CGMCC No. 33864. The strain has good tolerance to gastrointestinal juice and bile salts and has no hemolytic activity. Concentrated cell-free supernatant prepared from the strain can inhibit salmonella, including inhibiting the growth of salmonella, killing bacteria, inhibiting or removing biofilm. Animal experiments show that the strain and the concentrated cell-free supernatant thereof can prevent salmonella infection, alleviate weight loss caused by infection, maintain intestinal barrier integrity, reduce the level of pro-inflammatory factors, alleviate tissue damage, improve the expression of colon tight junction proteins and mucin, promote the generation of short-chain fatty acids, and restore the intestinal flora structure. The application further provides a microbial preparation containing the strain and / or the concentrated cell-free supernatant thereof. The strain and the microbial preparation can be used for preparing products for resisting salmonella, preventing salmonella infection or improving intestinal health.

The invention relates to the technical field of biological medicine, in particular to mussel mucin and hyaluronic acid cross-linked self-repairing eye health care cream and a 4D forming method thereof. The composition comprises stearic acid, cetostearyl alcohol and the like, a lactic acid bacteria fermentation extract, a jasmine flower extract, a wolfberry extract, a pseudo-ginseng extract, a cassia seed extract, a polygonum cuspidatum extract, a chrysanthemum extract, a leontopodium leontopodum extract, ethylparaben, methylparaben and the like, decapeptide-4, mussel mucin, proteoglycan protein and modified graphene. Modified graphene in the self-repairing eye health care cream can effectively promote crosslinking of mussel mucin and hyaluronic acid and improve the repairing effect, the micro-current effect of graphene can also promote skin tissue to absorb traditional Chinese medicine components and deeply repair eyes, the effect can be more obvious according to personal eye conditions and requirements, and the self-repairing eye health care cream has a good application prospect. The composition has the effects of relieving asthenopia, dryness and soreness, effectively delaying excessive growth of an ocular axis, relieving temporary myopia drift, relieving asthenopia and protecting near vision.

The invention relates to the field of cell culture and discloses a culture medium for thick-shelled mussel mantle cells and an application thereof. The culture medium comprises a basal culture medium and additives, wherein the additives comprise thick-shelled mussel serum, proanthocyanidins, bovine insulin, growth factors, antibiotics, defensins, mussel mucin and a buffer. The culture medium can be used for in vitro culture of thick-shelled mussel mantle cells and can better maintain the survival and growth of in vitro cultured thick-shelled mussel mantle cells. Defensins in a specific proportion are added to the culture medium, and the best growth and reproduction state can be achieved when the thick-shelled mussel mantle cells are cultured using the culture medium in the specific proportion. The application also provides an application method of the culture medium, which is simple to operate and can produce cultured thick-shelled mussel mantle cells with high cell density, good morphology and high wall adhesion.

Provided herein are multiepitope peptides comprising at least one mucin 1 (MUC1) peptide, having MHC affinity for at least one HLA serotype, and recognized by CD4+ T cell receptors and / or CD8+ T cell receptors. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various embodiments, the cationic lipid is R-DOTAP. The present invention also provides methods of using the multiepitope peptides, as well as compositions and vaccine compositions. These methods of use include methods for treating cancer in a subject and methods for inducing MUC-specific polyfunctional and cytolytic T cell responses in a subject.

The invention relates to a chemoenzymatic synthesis method of a high-glucose-type homogeneity mucoprotein core structural domain. The method comprises the following steps: firstly, catalytically synthesizing a key alpha-linked glycosylated amino acid block Fmoc-GalNacalpha-Ser / Thr-OH at a low temperature (-20 DEG C to 0 DEG C); then assembling the building blocks on a repeated polypeptide skeleton rich in proline, serine and threonine at accurate intervals (3-5 amino acid residues) through a solid-phase peptide synthesis technology to form a'sugar chain growth scaffold '; then, a series of high-specificity glycosyl transferases are used for carrying out sequential and directional sugar chain enzymatic extension on the scaffold, and a uniform core structure (such as a core type 3) is constructed; and finally, performing high-efficiency purification by a three-step series method of size exclusion chromatography, ion exchange chromatography and lectin affinity chromatography. The technical bottleneck of inhomogeneity (lt, 70%) of glycoforms in a traditional method is overcome, the mucoprotein core fragment with glycoform homogeneity larger than or equal to 95% and bioactivity highly similar to that of natural mucoprotein can be prepared on a large scale, and the method has wide application prospects in the biomedical fields of mucous membrane protective agents, drug delivery carriers and the like.

The invention relates to the technical field of medical biological materials, and discloses a mussel mucin-chondroitin sulfate composite hydrogel and a preparation method and application thereof, and the preparation method comprises the following steps: respectively preparing a mussel mucin aqueous solution and a chondroitin sulfate aqueous solution; the mass volume concentration of the mussel mucoprotein aqueous solution is 1%-10%, the mass volume concentration of the chondroitin sulfate aqueous solution is 1%-10%, the mass ratio of the mussel mucoprotein to the chondroitin sulfate is 3: 1-1: 3, the two solutions are mixed and stirred or oscillated under the conditions that the temperature is 4-37 DEG C and the pH value is 7.0-9.0, a cross-linking reaction is conducted, and hydrogel is formed; the cross-linking mode is physical cross-linking, chemical cross-linking or physical-chemical dual cross-linking; according to the invention, excellent tissue adhesion, injectability, self-healing property and biodegradability are realized, cell adhesion and proliferation can be effectively promoted, and the gel is suitable for various medical beauty scenes such as skin filling, wound repairing and anti-aging nursing.

The invention discloses a culture medium for colonization of intestinal flora and intestinal gas of gastrointestinal cancer crowds. The culture medium contains yeast extract, tryptone, mucoprotein, mycoprotein, insect protein, soybean protein, fructo-oligosaccharide, galactooligosaccharide, inulin, resistant dextrin, dietary fiber, porridge, vegetable juice, fruit juice, oat powder, coix seed powder, black bean powder, sialic acid, algal oil DHA, potassium chloride, sodium chloride, monopotassium phosphate, sodium sulfate, bile salt and a plant extract mixture. Vitamin mixed liquid and the like. By means of the bionic colon reactor, by referring to real in-vivo parameters of gastrointestinal cancer people, the real intestinal environment of domestic gastrointestinal cancer people is well simulated in vitro, the intestinal flora ecology and intestinal gas distribution are reproduced, and a normal intestinal microorganism and intestinal gas database of the gastrointestinal cancer people can be constructed. The method is beneficial to accurate diagnosis and personalized treatment of intestinal microecology of people with gastrointestinal cancer, and better evaluates the health state of people with gastrointestinal cancer and formulates preventive measures.

The present invention relates to Akkermansia muciniphila and its applications, belonging to the technical field of microbiology. The Akkermansia muciniphila described in the present invention is Akkermansia muciniphila SYSU-85, which was deposited on August 8, 2024 at the General Microbiological Center of the China General Microbiological Culture Collection Center, and its deposit number is: CGMCC NO. 46070. The Akkermansia muciniphila SYSU-85 of the present invention has a weak dependence on mucin, grows well in BHI medium supplemented with cysteine, and is resistant to oxaliplatin. The Akkermansia muciniphila SYSU-85 of the present invention alleviates the adverse reactions caused by oxaliplatin, and in combination with oxaliplatin or PD-1 inhibitor, significantly slows down the tumor growth curve and significantly reduces the tumor volume, improving the tumor treatment effect.

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Protocadherin 19 (PCDH19) RNA in a cell or subject, and in certain instances reducing the amount of PCDH19 protein in a cell or subject. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include PCDH19 Epilepsy. Such symptoms or hallmarks include seizures, cognitive impairment, intellectual disabilities, autism spectrum disorder, behavioral problems, aggression, anxiety, obsessive-compulsive disorder, hyperactivity, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).

This invention discloses a recombinant mussel adhesive protein, its preparation method, and its applications. The recombinant mussel adhesive protein includes a mussel adhesive protein tag, the amino acid sequence of which is shown in SEQ ID NO.2. The recombinant mussel adhesive protein is obtained by recombinantly fusing the aforementioned mussel adhesive protein tag with mussel adhesive protein, followed by in vitro hydroxylation modification. This recombinant mussel adhesive protein exhibits advantages such as high expression level, high purity, high Dopa content, high adhesion, and promotion of various cell growth mechanisms. It can be used in the preparation of adhesives or in the preparation of formulations that promote cell growth.

The invention discloses a culture medium for colonization of intestinal flora and intestinal gas of people with hyperuricemia. The culture medium contains yeast extract, ethanol, adenine, tryptone, mucoprotein, mycoprotein, insect protein, soybean protein, fructose, glucose, inulin, resistant dextrin, dietary fiber, oxalic acid, saturated fatty acid, sialic acid, peanut oil, potassium chloride, sodium chloride, monopotassium phosphate, sodium sulfate, bile salt, cysteine hydrochloride and a plant extract mixture. Vitamin mixed liquid and the like. By means of the bionic colon reactor, by referring to real in-vivo parameters of people suffering from hyperuricemia, the real intestinal environment of people suffering from hyperuricemia in China is well simulated in vitro, the intestinal flora ecology and intestinal gas distribution are reproduced, and a normal intestinal microorganism and intestinal gas database of people suffering from hyperuricemia can be constructed. The method is beneficial to accurate diagnosis of intestinal microecology of people with hyperuricemia, individualized treatment of antisense booking and disease mechanisms, better maintenance of intestinal health and formulation of preventive measures.

The invention discloses a preparation method of Chinese yam mucin anti-drag hydrogel. The preparation method comprises the following steps: crushing Chinese yam blocks and deionized water to obtain a Chinese yam mucus mixture; centrifuging, standing and layering, extracting supernate, and filtering to obtain a plant extracting solution; purifying by adopting a reverse osmosis method, and air-drying to obtain Chinese yam mucoprotein; the preparation method comprises the following steps: adding gelatin into a PBS solution, heating and stirring, then adding N, N-dimethylformamide and methacrylic anhydride, heating and stirring, dialyzing, and freeze-drying to obtain a gelatin derivative grafted with carbon-carbon double bonds; the preparation method comprises the following steps: adding a gelatin derivative into deionized water, heating and stirring, adding Chinese yam mucoprotein, N, N '-methylene bisacrylamide and ammonium persulfate, stirring, centrifugally defoaming, and drying to obtain the Chinese yam mucoprotein drag-reducing hydrogel. According to the preparation method of the Chinese yam mucoprotein anti-drag hydrogel, Chinese yam mucoprotein macromolecular chains are connected into a network structure by using N, N '-methylene bisacrylamide molecules, so that water-soluble Chinese yam mucoprotein is prevented from being dissolved and lost in a water body, and long-term lubrication and anti-drag are realized.

The invention provides a biological sustained-release stent as well as a preparation method and application thereof, and belongs to the technical field of biological materials. The biological sustained-release stent is prepared from the following raw materials in parts by weight: 35 parts of alkoxy-terminated polydimethylsiloxane, 15 parts of cyclopentanosiloxane, 5 parts of recombinant mussel mucin, 0.3 part of trifluoroacetic acid, 3 parts of trehalose and 2 parts of thioether-containing PTU polymer. The nucleotide sequence of the gene for coding the recombinant mussel mucin is as shown in SEQ ID NO. 1. According to the invention, the biological response type sustained-release stent is constructed through dynamic crosslinking of a mussel adhesive protein DOPA group and silicone molecules, and a wound microenvironment (pH / ROS) self-adaptive release function can be realized. The biological sustained-release scaffold is high in tensile strength and high in active ingredient retention rate, and various functional active ingredients in the biological scaffold have a synergistic effect.

Provided here relates to use of Akkermansia muciniphila or a composition containing Akkermansia muciniphila in preparation of a pharmaceutical composition or a health care product composition for improving metabolic syndrome. The Akkermansia muciniphila is Akkermansia muciniphila AM06, Akkermansia muciniphila AM02, or a combination thereof, the deposit number of Akkermansia muciniphila AM06 being CGMCC No. 22793, and the deposit number of the Akkermansia muciniphila AM02 being CGMCC No. 22794. The improvement of a metabolic syndrome comprises preventing and / or treating the metabolic syndrome.

The invention is applicable to the technical field of biopharmacy process, and provides a freeze-drying method for improving the bioactivity of recombinant mussel mucin, which comprises the steps of pretreatment, pre-freezing, primary drying and secondary drying. In the pretreatment step, a recombinant mussel mucoprotein solution with the pH value of 3.5-5.5 is mixed with a composite protective agent composed of trehalose, L-arginine and poloxamer according to a specific proportion; in the pre-freezing process, slow-fast-slow sectional cooling is adopted; drying adopts a vacuum drying mode combining gradient heating and gradient vacuum degree; according to the invention, creative coupling of the protective agent and the process is realized, the retention rate of the prepared product DOPA is more than 90%, the residual moisture is lower than 1.5%, the redissolution time is shorter than 30 seconds, the microstructure is excellent, and the long-term storage stability is good.

The present invention relates to a linker unit-cytotoxic small molecule drug, an antibody specifically binding to target mucoprotein 17 (MUC17), an antibody drug conjugate and uses thereof, and a composition and a detection system containing the antibody molecule, the linker unit-cytotoxic small molecule drug and the antibody drug conjugate.

The invention relates to the technical field of microcapsule preparation, in particular to a preparation method of a probiotic microcapsule. The preparation method comprises the following steps: mixing a probiotic suspension and a tris (2-carboxyethyl) phosphine solution, and carrying out a reduction reaction to obtain a thiolated probiotic suspension; and mixing the thiolated polysaccharide and the thiolated probiotic suspension, and carrying out a covalent ligation reaction to obtain the probiotic microcapsule. According to the preparation method disclosed by the invention, disulfide bonds on the surfaces of the probiotics are reduced into free mercaptan through simple chemical reaction, so that thiolated polysaccharide and the probiotics are covalently bound, and the polysaccharide and the probiotics are more firmly bound. The microcapsule prepared from the modified polysaccharide and the probiotics can also be combined with mucoprotein rich in the mucous layer of the intestinal tract to generate a catalyst-free thiol-disulfide exchange reaction, and colonization is carried out at the mucous layer in the intestinal tract, so that better intestinal disease treatment and probiotic benefits are generated.